|
|
 | |||||||||||||||||||||||||||||||||||||||||
 | |||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||
Background Neonatal conjunctivitis (ophthalmia neonatorum) continues to cause blindness, because the agents used prophylactically to prevent this condition are not completely effective and are not widely available in many parts of the world. Povidone–iodine ophthalmic solution is an effective antibacterial agent with broad antibacterial and antiviral activity to which no bacteria are known to be resistant, and it is far less expensive and less toxic than the agents currently used to prevent neonatal conjunctivitis.
Methods We conducted a masked, prospective trial involving 3117 infants born over a period of 30 months in a hospital in Kenya. Shortly after birth each infant received a 2.5 percent solution of povidone–iodine (n = 1076), a 1 percent solution of silver nitrate (n = 929), or 0.5 percent erythromycin ointment (n = 1112) in both eyes. Randomization was achieved by rotating the three medications after each was used for a week.
Results Of the neonates treated with povidone–iodine, 13.1 percent had infectious conjunctivitis, as compared with 17.5 percent of those treated with silver nitrate (P<0.001) and 15.2 percent of those treated with erythromycin (P = 0.01). Povidone–iodine was more effective against Chlamydia trachomatis than was silver nitrate (P<0.001) or erythromycin (P = 0.008). There were 104 cases of noninfectious conjunctivitis (9.7 percent) in the povidone–iodine group, as compared with 129 in the silver nitrate group (13.9 percent, P<0.001) and 148 in the erythromycin group (13.3 percent, P = 0.004). Many cases of noninfectious conjunctivitis were probably due to a toxic reaction to the treatment itself. The incidence of Neisseria gonorrhoeae and Staphylococcus aureus infections was similar in the three groups.
Conclusions A 2.5 percent ophthalmic solution of povidone–iodine as prophylaxis against ophthalmia neonatorum is more effective than treatment with silver nitrate or erythromycin, and it is less toxic and costs less.
Source Information
From the Department of Ophthalmology, Jules Stein Eye Institute, Harbor–UCLA Medical Center, UCLA School of Medicine, Los Angeles and Torrance, Calif. (S.J.I., L.A.); and the Eye Department, Presbyterian Church Hospital, Kikuyu, Kenya (M.W.).
Address reprint requests to Dr. Isenberg at the Jules Stein Eye Institute, UCLA School of Medicine, 100 Stein Plaza, Los Angeles, CA 90024-7001.
Related Letters:
Povidone-Iodine to Prevent Ophthalmia Neonatorum
Rotta A. T., Petri A. R., Pietsch M., Barton L. L., Isenberg S. J., Apt L., Foster A.
Extract |
Full Text
N Engl J Med 1995;
333:126-127, Jul 13, 1995.
Correspondence
This article has been cited by other articles:
HOME | SUBSCRIBE | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | PRIVACY | TERMS OF USE | HELP | beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved. |
Previous
